Cytek Biosciences, Inc.

Valuation Analysis

About the Company

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle detection; Cytek amnis imagestream imaging flow cytometers; Cytek guava muse cell analyzers; Cytek muse micro cell analyzers; Cytek guava easyCyte flow cytometers; and Cytek orion reagent cocktail preparation systems. It also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of i

Cytek Biosciences, Inc. Stock at a Glance

Cytek Biosciences, Inc. (CTKB) is currently trading at $3.96 with a market capitalization of $511.4M. The 52-week range spans from $2.90 to $6.18; the current price is 35.9% below the yearly high. Year-over-year revenue growth stands at +6.5%.

💰 Dividend

Cytek Biosciences, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Analyst Rating

4 analysts rate Cytek Biosciences, Inc. (CTKB) on consensus: None. The average price target is $5.69, implying +43.62% from the current price. Analyst price targets range from $4.75 to $7.50.

Cytek Biosciences, Inc.: The Investment Case in Detail

Cytek Biosciences, Inc. (CTKB) operates in the Healthcare — specifically Medical Devices — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bear Case

Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders.

What to Watch Next

• The analyst consensus price target implies 43.62% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Risk Profile

The data points to market-like volatility, elevated short interest (7.17%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Cytek Biosciences, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.